Journal of Pulmonology and Respiratory Diseases
Open Access

Sleep apnea; Cardiovascular disease; Hypertension; Coronary artery disease; Heart failure; Arrhythmias; Continuous positive airway pressure (CPAP); Oxidative stress; Sympathetic nervous system; Inflammation.

Introduction

Sleep apnea is a common yet often underdiagnosed disorder that significantly impacts the quality of life and is associated with severe health consequences. The condition primarily manifests as obstructive sleep apnea (OSA), where repeated apneas (pauses in breathing) occur during sleep due to partial or complete upper airway collapse [1]. The most alarming aspect of OSA is its established link with cardiovascular morbidity and mortality. Cardiovascular risk factors such as hypertension, arrhythmias, coronary artery disease (CAD), and heart failure are frequently observed in patients with sleep apnea. Consequently, addressing sleep apnea not only improves sleep quality but may also reduce cardiovascular risk, making it an essential component in the management of patients with coexisting sleep and heart disorders [2].

Mechanisms linking sleep apnea to cardiovascular risk

The mechanisms by which sleep apnea contributes to cardiovascular disease are multifactorial and involve both direct and indirect pathways.

Intermittent hypoxia and reoxygenation: One of the hallmark features of sleep apnea is intermittent hypoxia, wherein oxygen levels drop during apneas and then rapidly increase during recovery. This fluctuation in oxygen saturation leads to oxidative stress and inflammation, both of which are key contributors to endothelial dysfunction and the development of atherosclerosis [3]. Repeated cycles of hypoxia and reoxygenation are thought to damage the vascular endothelium, leading to the initiation of atherosclerotic processes.

Sympathetic nervous system activation: The apnea-related disruption of normal breathing triggers a significant increase in sympathetic nervous system activity. This increased sympathetic tone contributes to elevated blood pressure and heart rate, both of which are risk factors for the development of hypertension and other cardiovascular conditions. Furthermore, the persistent activation of the sympathetic nervous system may contribute to arrhythmias and heart failure.

Inflammation and endothelial dysfunction: Sleep apnea has been associated with systemic inflammation, which contributes to the pathogenesis of cardiovascular diseases. Recurrent apneas activate inflammatory pathways, increasing levels of pro-inflammatory cytokines such as C-reactive protein (CRP) and interleukins (e.g., IL-6) [4]. These cytokines can damage endothelial cells, impair nitric oxide production, and reduce vasodilation, leading to increased vascular stiffness, a key risk factor for hypertension and CAD.

Altered hemodynamics and vascular remodeling: The fluctuations in intrathoracic pressure caused by obstructive apneas contribute to abnormal hemodynamics. This can result in increased afterload on the heart, affecting both systolic and diastolic function. Over time, this altered hemodynamics may lead to structural changes in the heart, such as left ventricular hypertrophy, which is a well-known risk factor for heart failure.

Coagulation abnormalities: Patients with sleep apnea also exhibit increased activation of the coagulation system, resulting in a hypercoagulable state. Increased fibrinogen levels, elevated D-dimer concentrations, and other markers of coagulation are commonly observed in individuals with OSA [5]. These changes heighten the risk of thromboembolic events, including stroke and myocardial infarction.

Implications of sleep apnea on cardiovascular health

Hypertension: One of the most significant cardiovascular risks associated with sleep apnea is the development of hypertension. Studies have shown that individuals with OSA are more likely to develop both primary and resistant hypertension, with nighttime blood pressure rising significantly during apneic events. The elevated sympathetic tone, intermittent hypoxia, and systemic inflammation all contribute to this increased blood pressure [6]. Importantly, the treatment of OSA with continuous positive airway pressure (CPAP) therapy has been shown to reduce blood pressure, providing a potential therapeutic avenue.

Coronary artery disease and myocardial infarction: The relationship between sleep apnea and CAD is well-documented. The inflammation and oxidative stress triggered by sleep apnea may accelerate the development of atherosclerosis. Additionally, the intermittent drops in oxygen saturation and increased sympathetic activity can increase the likelihood of plaque rupture and thrombosis, potentially leading to myocardial infarction [7]. It has been observed that patients with sleep apnea who also suffer from CAD experience worse outcomes, including increased rates of hospitalization and mortality.

Arrhythmias: The link between sleep apnea and arrhythmias, particularly atrial fibrillation (AF), is an area of intense research. The intermittent hypoxia and increased sympathetic activity associated with OSA are thought to create an arrhythmic substrate, particularly in the atria [8]. OSA has been shown to increase the risk of AF, and treatment of sleep apnea has been associated with improved rhythm control in patients with AF.

Heart failure: Sleep apnea, especially central sleep apnea, is a common comorbidity in patients with heart failure. The apneas lead to swings in intrathoracic pressure, further exacerbating the strain on the heart. The resulting sympathetic activation, fluid retention, and altered autonomic regulation of cardiac function contribute to worsening heart failure [9]. Interestingly, managing sleep apnea in these patients with CPAP therapy has shown promise in improving cardiac function and reducing hospitalization rates.

Stroke: There is a clear association between sleep apnea and an increased risk of ischemic and hemorrhagic stroke. The pathophysiological mechanisms behind this include elevated blood pressure, coagulation abnormalities, and intermittent hypoxia. Moreover, individuals with OSA are at higher risk of developing atrial fibrillation, further increasing the risk of embolic strokes.

Clinical Interventions to Address Cardiovascular Risk

Continuous positive airway pressure (CPAP): CPAP therapy is the gold standard treatment for moderate to severe OSA. By providing a continuous flow of air that keeps the upper airway open, CPAP prevents apneas and hypopneas, thereby improving oxygenation and reducing sympathetic nervous system activation. CPAP therapy has shown benefits in reducing blood pressure, improving left ventricular function, and decreasing hospital admissions for heart failure exacerbations.

Lifestyle modifications: Weight loss, a key intervention for managing OSA, has been shown to improve both sleep apnea severity and cardiovascular risk [10]. A healthy diet, regular physical activity, and smoking cessation are fundamental strategies that not only improve sleep apnea symptoms but also reduce hypertension, improve lipid profiles, and enhance overall cardiovascular health.

Pharmacological therapy: While CPAP remains the cornerstonse of OSA treatment, pharmacological approaches may be used as adjuncts, particularly in patients with residual symptoms or those unable to tolerate CPAP. Medications that target the underlying mechanisms of OSA, such as those that reduce sympathetic tone or promote smooth muscle relaxation in the airway, may be useful. However, pharmacological interventions are not a substitute for CPAP therapy and are generally used in conjunction with other treatment modalities.

Surgical interventions: In some cases, surgical options such as uvulopalatopharyngoplasty (UPPP), mandibular advancement devices, or even bariatric surgery may be considered, especially in patients with severe anatomical obstructions or those who do not respond to CPAP therapy. Surgical interventions can help address the mechanical factors contributing to airway collapse during sleep.

Management of comorbid conditions: Effective management of cardiovascular comorbidities, including hypertension, heart failure, and atrial fibrillation, is crucial in individuals with sleep apnea. Targeting these conditions while simultaneously treating OSA can improve patient outcomes and reduce the cardiovascular burden.

Conclusion

Sleep apnea is a significant risk factor for the development and exacerbation of cardiovascular diseases. Understanding the pathophysiological mechanisms linking sleep apnea and cardiovascular risk, such as intermittent hypoxia, sympathetic activation, and inflammation, is critical for improving patient care. Interventions like CPAP therapy, lifestyle modifications, and management of comorbid conditions offer substantial benefits in reducing cardiovascular risk and improving overall health. Early recognition and treatment of sleep apnea are essential in preventing the long-term cardiovascular complications that arise from this common disorder. Through comprehensive management, patients with sleep apnea can experience improved cardiovascular outcomes, reducing both morbidity and mortality.

1. Mello RD, Dickenson AH (2008) Spinal cord mechanisms of pain. BJA 101: 8-16.

Indexed at, Google Scholar, Crossref

2. liddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, et al (2000) A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthr Cartil 8: 9-12.

Indexed at, Google Scholar, Crossref

3. Maroon JC, Bost JW, Borden MK, Lorenz KM, Ross NA, et al. (2006) Natural anti-inflammatory agents for pain relief in athletes. Neurosurg Focus 21: 1-13.

Indexed at, Google Scholar, Crossref

4. Birnesser H, Oberbaum M, Klein P, Weiser M (2004) The Homeopathic Preparation Traumeel® S Compared With NSAIDs For Symptomatic Treatment Of Epicondylitis. J Musculoskelet Res 8: 119-128.

Indexed at, Google Scholar, Crossref

5. Gergianaki I, Bortoluzzi A, Bertsias G (2018) Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 32: 188-205.

Indexed at, Google Scholar, Crossref

6. Cunningham AA, Daszak P, Wood JLN (2017) One Health, emerging infectious diseases and wildlife: two decades of progress? Phil Trans 372: 1-8.

IndexedAt, Google Scholar, Crossref

7. Sue LJ (2004) Zoonotic poxvirus infections in humans. Curr Opin Infect Dis MN 17: 81-90.

Indexed at, Google Scholar, Crossref

8. Pisarski K (2019) The global burden of disease of zoonotic parasitic diseases: top 5 contenders for priority consideration. Trop Med Infect Dis 4: 1-44.

Indexed at, Google Scholar, Crossref

9. Kahn LH (2006)Confronting zoonoses, linking human and veterinary medicine. Emerg Infect Dis 12:556-561.

Indexed at, Google Scholar, Crossref

10. Bidaisee S, Macpherson CN (2014) Zoonoses and one health: a review of the literature. J Parasitol 2014: 1-8.

Indexed at, Google Scholar, Crossref